Constitutive IRF8 Expression Inhibits AML by Activation of Repressed Immune Response Signaling

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2014 Jun 25

PMID 24957708

Citations 17

Authors

A Sharma

H Yun

N Jyotsana

A Chaturvedi

A Schwarzer

E Yung

C K Lai

F Kuchenbauer

B Argiropoulos

K Gorlich

A Ganser

R K Humphries

M Heuser

Affiliations

Soon will be listed here.

Abstract

Myeloid differentiation is blocked in acute myeloid leukemia (AML), but the molecular mechanisms are not well characterized. Meningioma 1 (MN1) is overexpressed in AML patients and confers resistance to all-trans retinoic acid-induced differentiation. To understand the role of MN1 as a transcriptional regulator in myeloid differentiation, we fused transcriptional activation (VP16) or repression (M33) domains with MN1 and characterized these cells in vivo. Transcriptional activation of MN1 target genes induced myeloproliferative disease with long latency and differentiation potential to mature neutrophils. A large proportion of differentially expressed genes between leukemic MN1 and differentiation-permissive MN1VP16 cells belonged to the immune response pathway like interferon-response factor (Irf) 8 and Ccl9. As MN1 is a cofactor of MEIS1 and retinoic acid receptor alpha (RARA), we compared chromatin occupancy between these genes. Immune response genes that were upregulated in MN1VP16 cells were co-targeted by MN1 and MEIS1, but not RARA, suggesting that myeloid differentiation is blocked through transcriptional repression of shared target genes of MN1 and MEIS1. Constitutive expression of Irf8 or its target gene Ccl9 identified these genes as potent inhibitors of murine and human leukemias in vivo. Our data show that MN1 prevents activation of the immune response pathway, and suggest restoration of IRF8 signaling as therapeutic target in AML.

Citing Articles

Epigenetic control over the cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia.

Felipe Fumero E, Walter C, Frenz J, Seifert F, Alla V, Hennig T Blood. 2024; 143(22):2284-2299.

PMID: 38457355 PMC: 11181352. DOI: 10.1182/blood.2023021640.

LSD1 inhibition modulates transcription factor networks in myeloid malignancies.

Hartung E, Singh K, Berg T Front Oncol. 2023; 13:1149754.

PMID: 36969082 PMC: 10036816. DOI: 10.3389/fonc.2023.1149754.

IRF8: Mechanism of Action and Health Implications.

Moorman H, Reategui Y, Poschel D, Liu K Cells. 2022; 11(17).

PMID: 36078039 PMC: 9454819. DOI: 10.3390/cells11172630.

Transcriptional Plasticity Drives Leukemia Immune Escape.

Eagle K, Harada T, Kalfon J, Perez M, Heshmati Y, Ewers J Blood Cancer Discov. 2022; 3(5):394-409.

PMID: 35709529 PMC: 9897290. DOI: 10.1158/2643-3230.BCD-21-0207.

ILC1s control leukemia stem cell fate and limit development of AML.

Li Z, Ma R, Ma S, Tian L, Lu T, Zhang J Nat Immunol. 2022; 23(5):718-730.

PMID: 35487987 PMC: 9106917. DOI: 10.1038/s41590-022-01198-y.

References

Ji X, Li W, Song J, Wei L, Liu X . CEAS: cis-regulatory element annotation system. Nucleic Acids Res. 2006; 34(Web Server issue):W551-4. PMC: 1538818. DOI: 10.1093/nar/gkl322. View

Hu G, Cui K, Northrup D, Liu C, Wang C, Tang Q . H2A.Z facilitates access of active and repressive complexes to chromatin in embryonic stem cell self-renewal and differentiation. Cell Stem Cell. 2012; 12(2):180-92. PMC: 3570599. DOI: 10.1016/j.stem.2012.11.003. View

Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A . Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010; 116(17):3171-9. DOI: 10.1182/blood-2010-03-276196. View

Krebs A, Frontini M, Tora L . GPAT: retrieval of genomic annotation from large genomic position datasets. BMC Bioinformatics. 2008; 9:533. PMC: 2654044. DOI: 10.1186/1471-2105-9-533. View

Haferlach C, Kern W, Schindela S, Kohlmann A, Alpermann T, Schnittger S . Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia. Genes Chromosomes Cancer. 2011; 51(3):257-65. DOI: 10.1002/gcc.20950. View

Li L, Jin H, Xu J, Shi Y, Wen Z . Irf8 regulates macrophage versus neutrophil fate during zebrafish primitive myelopoiesis. Blood. 2010; 117(4):1359-69. DOI: 10.1182/blood-2010-06-290700. View

Rosenbauer F, Tenen D . Transcription factors in myeloid development: balancing differentiation with transformation. Nat Rev Immunol. 2007; 7(2):105-17. DOI: 10.1038/nri2024. View

Schmidt M, Nagel S, Proba J, Thiede C, Ritter M, Waring J . Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood. 1998; 91(1):22-9. View

Watanabe-Okochi N, Kitaura J, Ono R, Harada H, Harada Y, Komeno Y . AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood. 2008; 111(8):4297-308. DOI: 10.1182/blood-2007-01-068346. View

10.

Unnisa Z, Clark J, Roychoudhury J, Thomas E, Tessarollo L, Copeland N . Meis1 preserves hematopoietic stem cells in mice by limiting oxidative stress. Blood. 2012; 120(25):4973-81. PMC: 3525022. DOI: 10.1182/blood-2012-06-435800. View

11.

van Wely K, Molijn A, Buijs A, Meester-Smoor M, Aarnoudse A, Hellemons A . The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR-mediated transcription. Oncogene. 2003; 22(5):699-709. DOI: 10.1038/sj.onc.1206124. View

12.

Heuser M, Beutel G, Krauter J, Dohner K, von Neuhoff N, Schlegelberger B . High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood. 2006; 108(12):3898-905. DOI: 10.1182/blood-2006-04-014845. View

13.

Holtschke T, Lohler J, Kanno Y, Fehr T, Giese N, Rosenbauer F . Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell. 1996; 87(2):307-17. DOI: 10.1016/s0092-8674(00)81348-3. View

14.

Schwind S, Marcucci G, Kohlschmidt J, Radmacher M, Mrozek K, Maharry K . Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. Blood. 2011; 118(15):4188-98. PMC: 3291490. DOI: 10.1182/blood-2011-06-357764. View

15.

Langer C, Marcucci G, Holland K, Radmacher M, Maharry K, Paschka P . Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2009; 27(19):3198-204. PMC: 2716941. DOI: 10.1200/JCO.2008.20.6110. View

16.

Nardi V, Naveiras O, Azam M, Daley G . ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines. Blood. 2009; 113(16):3813-20. PMC: 2670796. DOI: 10.1182/blood-2008-07-167189. View

17.

Schmidt M, Hochhaus A, Nitsche A, Hehlmann R, Neubauer A . Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha. Blood. 2001; 97(11):3648-50. DOI: 10.1182/blood.v97.11.3648. View

18.

Heuser M, Argiropoulos B, Kuchenbauer F, Yung E, Piper J, Fung S . MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood. 2007; 110(5):1639-47. DOI: 10.1182/blood-2007-03-080523. View

19.

Bergerson R, Collier L, Sarver A, Been R, Lugthart S, Diers M . An insertional mutagenesis screen identifies genes that cooperate with Mll-AF9 in a murine leukemogenesis model. Blood. 2012; 119(19):4512-23. PMC: 3362364. DOI: 10.1182/blood-2010-04-281428. View

20.

Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg A, Sauvageau G . Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J. 1998; 17(13):3714-25. PMC: 1170707. DOI: 10.1093/emboj/17.13.3714. View